Reimbursement Decisions Logo
Guest | Login/Register
Your foremost guide to global pricing and reimbursement decisions.TM

pCODR Reimbursement Decisions Database

The searchable, online version of the pCODR Decisions database contains all recommendations from establishment of pCODR and is updated regularly. The pCODR Decisions database is currently available without registration for the year 2012. For full access to the pCODR database, please register. For custom analyses, please contact us.

Filter your results:
Brand Name: Generic Drug Name:
Manufacturer: Indication:
Recommendation Summary:




Year:





12 Records Total
Brand Name Generic Name Manufacturer Indication Funding Request Recommendation Summary Recommen-
dation Date
Afinitor Everolimus Novartis Pharmaceuticals Canada Inc. Pancreatic Neuroendocrine Tumours Patients with well- or moderately differentiated neuroendocrine tumours of pancreatic origin (pNETs) in patients with unresectable, locally advanced or metastatic disease. Recommended - conditional on improved cost-effectiveness. 2012-08-30
Halaven Eribulin Mesylate Eisai Limited Metastatic Breast Cancer For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane administered in either the adjuvant or metastatic setting. Recommended - conditional on improved cost-effectiveness. 2012-08-02
Sutent Sunitinib Malate Pfizer Canada Inc. Pancreatic Neuroendocrine Tumours Patients with unresectable locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNETs), whose disease is progressive. Recommended - conditional on improved cost-effectiveness. 2012-05-03
Treanda Bendamustine Hydrochloride Lundbeck Canada Inc. Chronic Lymphocytic Leukemia For the treatment of patients with chronic lymphocytic leukemia (relapsed/refractory) for whom fludarabine-based therapy is not appropriate. Not recommended - clinical benefit insufficient/unclear. 2012-11-29
Treanda Bendamustine Hydrochloride Lundbeck Canada Inc. Non-Hodgkin Lymphoma For the treatment of patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL) (first-line). Recommended - without criteria/conditions. 2012-11-29
Treanda Bendamustine Hydrochloride Lundbeck Canada Inc. Non-Hodgkin Lymphoma For the treatment of patients with indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL) (relapsed/refractory). Recommended - with criteria/conditions. 2012-11-29
Votrient Pazopanib Hydrochloride GlaxoSmithKline Inc. Soft Tissue Sarcoma Adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Funding is not requested for patients with GIST and adipocytic soft tissue sarcomas. Not recommended - clinical benefit insufficient/unclear and cost-effectiveness insufficient/unclear. 2012-11-29
Votrient (Original Submission) Pazopanib Hydrochloride GlaxoSmithKline Inc. Metastatic Renal Cell Carcinoma First-line therapy in patients with metastatic renal cell (clear cell) carcinoma who have a Memorial Sloan Kettering prognostic score of favourable or intermediate risk. Recommended - with criteria/conditions. 2012-01-05
Xalkori (Original Submission) Crizotinib Pfizer Canada Inc. Advanced Non-Small Cell Lung Cancer Patients with anaplastic lymphoma kinase-(ALK) positive advanced non-small cell lung cancer (NSCLC). Not recommended - clinical benefit insufficient/unclear. 2012-10-04
Yervoy Ipilimumab Bristol-Myers Squibb Canada Advanced Melanoma Treatment of advanced melanoma (unresectable Stage III and IV melanoma) in patients who have received prior systemic therapy. Recommended - conditional on improved cost-effectiveness. 2012-04-18
Zelboraf Vemurafenib Hoffmann-La Roche Ltd. Advanced Melanoma Treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma (first-line). Recommended - conditional on improved cost-effectiveness. 2012-06-01
Zelboraf Vemurafenib Hoffmann-La Roche Ltd. Advanced Melanoma Treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma (second-line). Not recommended - clinical benefit insufficient/unclear and cost-effectiveness insufficient/unclear. 2012-06-01

12 Records Total

Return to Top